AR124604A1 - Mutantes de fimh, composiciones con los mismos y uso de los mismos - Google Patents

Mutantes de fimh, composiciones con los mismos y uso de los mismos

Info

Publication number
AR124604A1
AR124604A1 ARP220100049A ARP220100049A AR124604A1 AR 124604 A1 AR124604 A1 AR 124604A1 AR P220100049 A ARP220100049 A AR P220100049A AR P220100049 A ARP220100049 A AR P220100049A AR 124604 A1 AR124604 A1 AR 124604A1
Authority
AR
Argentina
Prior art keywords
fimh
lectin domain
compositions
mutants
polypeptides
Prior art date
Application number
ARP220100049A
Other languages
English (en)
Inventor
Jan Grijpstra
Eveline Marleen Weerdenbburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AR124604A1 publication Critical patent/AR124604A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen polipéptidos que comprenden un dominio de lectina de FimH que comprenden al menos una mutación de aminoácidos que hace que el dominio de lectina de FimH esté en la conformación de baja afinidad por manosa. Se describen adicionalmente composiciones farmacéuticas que comprenden dichos polipéptidos y métodos para estimular una respuesta inmunitaria en un sujeto que lo necesita mediante la administración del polipéptido. Reivindicación 1: Un polipéptido que comprende un dominio de lectina de FimH que comprende Tirosina (Y) o Triptófano (W) en la posición que corresponde a la posición 71 en la SEQ ID Nº 1.
ARP220100049A 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con los mismos y uso de los mismos AR124604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12

Publications (1)

Publication Number Publication Date
AR124604A1 true AR124604A1 (es) 2023-04-12

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100049A AR124604A1 (es) 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con los mismos y uso de los mismos

Country Status (12)

Country Link
US (2) US11725028B2 (es)
EP (1) EP4277921A1 (es)
JP (1) JP2024502854A (es)
KR (1) KR20230125842A (es)
CN (1) CN116888140A (es)
AR (1) AR124604A1 (es)
AU (1) AU2022207740B2 (es)
CA (1) CA3207841A1 (es)
IL (1) IL303954A (es)
MX (1) MX2023008251A (es)
TW (1) TW202241929A (es)
WO (1) WO2022153166A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
WO2023111907A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
JP2003519084A (ja) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP1194563A1 (en) * 1999-07-15 2002-04-10 Medimmune, Inc. Fimh adhesin-based vaccines
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
DE60134499D1 (de) 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
EP1299544A2 (en) 2000-07-07 2003-04-09 Medimmune, Inc. Fimh adhesin proteins and methods of use
AU2001218049A1 (en) * 2000-08-18 2002-03-04 Med Immune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
AU2001297896A1 (en) 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
US8753864B2 (en) 2005-05-11 2014-06-17 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
LT2257307T (lt) 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
JP2018515517A (ja) * 2015-05-13 2018-06-14 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ 尿路病原性大腸菌感染病の処置と予防のための組成物および方法
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019048871A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol PROTEIN ADMINISTRATION TO MEMBRANES
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
WO2021123360A1 (en) * 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
JP7485771B2 (ja) * 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用

Also Published As

Publication number Publication date
US20230406890A1 (en) 2023-12-21
KR20230125842A (ko) 2023-08-29
CN116888140A (zh) 2023-10-13
AU2022207740A1 (en) 2023-06-29
JP2024502854A (ja) 2024-01-23
AU2022207740B2 (en) 2024-06-06
TW202241929A (zh) 2022-11-01
US11725028B2 (en) 2023-08-15
IL303954A (en) 2023-08-01
US20220220159A1 (en) 2022-07-14
EP4277921A1 (en) 2023-11-22
WO2022153166A1 (en) 2022-07-21
MX2023008251A (es) 2023-07-26
CA3207841A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
AR114445A1 (es) Conjugados de il-15, y sus usos
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20231648A1 (es) CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
AR104635A1 (es) COMPOSICIONES A BASE DE LISTERIA INMUNOGÉNICA QUE COMPRENDEN FUSIONES DE ANTÍGENO Y ActA TRUNCADA Y MÉTODOS DE USO DE ESTAS
BRPI0809926B8 (pt) composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
ES2103295T3 (es) Secuencia nucleotida codificante para una proteina de la membrana externa de neisseria meningitidis, y su utilizacion en la preparacion de vacunas.
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
PE20212265A1 (es) Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos
BR112018075785A2 (pt) formulação de vacina para o hiv
AR120096A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
BR112021023957A2 (pt) Peptídeos
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
ATE389397T1 (de) Adjuvante zusammensetzungen
Noya et al. A mucin-like peptide from Fasciola hepatica instructs dendritic cells with parasite specific Th1-polarizing activity
CL2022000094A1 (es) Anticuerpos anti-cd63, conjugados y usos de estos (divisional de la solicitud no. 202002965)
BR112023004819A2 (pt) Composições de vacinas multivalentes e seus usos
PE20221271A1 (es) Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
AR115537A1 (es) Terapia combinada con una vacuna neoantigénica